← Leaderboards
Sylvia Adams
New York University School Of Medicine
$1,535,260
Attributed
$2,379,580
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $517.3K · FY2007–15$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$2,379,580 · 2
By mechanism
R01$1,688,640 · 1
K23$690,940 · 1
Top collaborators
- Silvia C Formenti5 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Sandra Demaria$8,493,423
- Benjamin G. Neel$33,134,772
- Silvia C Formenti$2,888,589
- Franco M Muggia$5,360,861
- Sungheon Gene Kim$10,134,654
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseVaccinatedModalityMalignant NeoplasmsSafetyTumorClinical TrialsDendritic CellsImmune ResponseImmunogenicMonitorResponseT-LymphocyteTranslatingAdjuvantClinical InvestigatorAntigensCancer ImmunotherapyCancer PatientAgonistImmunityCd8b1 GeneHuman Tlr7 ProteinAdverse Event
Grant awards (10)
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$373,301
R01 · FY2015 · CA
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$206,156
R01 · FY2014 · CA
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$353,046
R01 · FY2013 · CA
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$377,228
R01 · FY2012 · CA
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.$378,909
R01 · FY2011 · CA
Augmenting Cancer Vaccine Therapy with TLR9 agonists$138,348
K23 · FY2011 · CA · contact PI
Augmenting Cancer Vaccine Therapy with TLR9 agonists$138,348
K23 · FY2010 · CA · contact PI
Augmenting Cancer Vaccine Therapy with TLR9 agonists$138,348
K23 · FY2009 · CA · contact PI
Augmenting Cancer Vaccine Therapy with TLR9 agonists$137,548
K23 · FY2008 · CA · contact PI
Augmenting Cancer Vaccine Therapy with TLR9 agonists$138,348
K23 · FY2007 · CA · contact PI